AstraZeneca Expands U.S. Footprint to Power the Future of Cell Therapy

AstraZeneca’s investment in Maryland creates high-quality jobs and advances next-generation cancer treatments. 

AstraZeneca has announced the opening of a sustainable, state-of-the-art cell therapy manufacturing facility in Rockville, Maryland. This site will bring over 150 highly skilled STEM jobs to the region and boost the local economy. The facility will support clinical trials for next-generation T-cell therapies aimed at treating some of the most challenging cancers and diseases, building on America’s leadership in cancer therapy innovation. 

This investment is part of a broader U.S. expansion that includes R&D hubs and advanced manufacturing sites across the country. It is a manifestation of AstraZeneca’s commitment to cutting-edge innovation, community investment and U.S. manufacturing leadership. In the words of Maryland Lieutenant Governor Aruna Miller, “AstraZeneca isn’t just advancing science, it’s also shaping the future of Maryland’s workforce.”

A modern building with large glass windows and vertical brown metal accents, surrounded by greenery and a sidewalk; the sky is clear and blue.